Alex Francoeur

Alex Francoeur

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
AFAlex Francoeur
Alex Francoeur
BMBradley J. Monk
Bradley J. Monk
KTKrishnansu S. Tewari
Krishnansu S. Tewari

18 August 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
AFAlex Francoeur
Alex Francoeur
CLCheng-I Liao
Cheng-I Liao
MCMichelle Ann Casear
Michelle Ann Casear
ACAva Chan
Ava Chan
DKDaniel S Kapp
Daniel S Kapp
JCJohn K Chan
John K Chan
Objective Cervical cancer (International Federation of Gynecology and Obstetrics (FIGO)) stage IVA-B (distant stage) is a rare diagnosis with an approximate 5 year survival rate of 17% and with limited treatment options. The objective of this study was to determine the trends in distant stage cervical cancer in the USA and identify possible factors related to these trends. Methods Data were obtained from the United States Cancer Statistics program from 2001 to 2018. Rates of cervical cancer screening and vaccination were evaluated using the Behavioral Risk Factor Surveillance System and TeenVaxView. SEER*Stat 8.3.8.9.2 and Joinpoint regression program 4.9.0.0 were used to calculate incidence trends. Results Over the last 18 years, 29 715 women were diagnosed with distant stage cervical carcinoma. Black women have disproportionately higher rates at 1.55/100 000 versus 0.92/100 000 in White women (p<0.001). When examining the trends over time, there has been an annual increase in distant stage cervical cancer at a rate of 1.3% per year (p<0.001). The largest increase is seen in cervical adenocarcinoma with an average annual percent change of 2.9% (p<0.001). When performing an intersection analysis of race, region and age, White women in the South aged 40–44 have the highest rise in distant cervical cancer at a rate of 4.5% annually (p<0.001). Using the Behavioral Risk Factor Surveillance System and TeenVax data, compared with Black women, we found that White women have a nearly two-fold higher rate of missed or lack of guideline screening, 26.6% vs 13.8%. White teenagers (13–17 years) have the lowest human papillomavirus vaccination rate at 66.1% compared with others at 75.3%. Conclusions Black women have a higher incidence of distant stage disease compared with White women. However, White women have a greater annual increase, particularly in adenocarcinomas. Compared with Black women, White women also have lower rates of guideline screening and vaccination.

2 January 2025 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
AFAlex Francoeur
Alex Francoeur
CLCheng-I Liao
Cheng-I Liao
JCJenny Chang
Jenny Chang
CJCaitlin R. Johnson
Caitlin R. Johnson
KCKiran Clair
Kiran Clair
RBRobert E. Md Bristow
Robert E. Md Bristow
OBJECTIVE: To evaluate the correlation in temporal trends in obesity and endometrioid endometrial cancer incidence in the United States using two comprehensive national databases. METHODS: This is a cohort study in which data on endometrioid endometrial cancer were obtained from the U.S. Cancer Statistics from 2001 to 2018 and corrected for hysterectomy and pregnancy. Data on obesity were collected from the NHANES (National Health and Nutrition Examination Survey) database from 1988 to 2018. Average annual percentage changes (AAPCs) were used to describe trends. Pearson correlation coefficients (r) were calculated to examine the relationship between trends. SEER*Stat 8.3.9.2 and joinpoint regression program 5.2.0 were used for statistical analysis. RESULTS: From U.S. Cancer Statistics data, 586,742 cases of endometrioid cancer were identified from 2001 to 2018. The average annual increase in endometrioid cancer was as follows: Hispanic 1.37% (95% CI, 1.14–1.60, P<.001), Black 1.30% (95% CI, 1.04–1.57, P<.001), and White −0.17 (95% CI, −0.91 to 0.58, P=.656). Women aged 20–29 years had a 4.48% annual increase (95% CI, 3.72–5.25, P<.001) and women aged 30–39 years had a 3.00% annual increase in rates (95% CI, 2.65–3.36, P<.001). According to the NHANES data, the prevalence of obesity in 2018 in adult women was as follows: Black 56.80%, Hispanic 44.10%, and White 40.90%. An examination of trends by age showed that women aged 20–29 years had the highest annual rise in obesity compared with other age groups (AAPC 7.36%, 95% CI, 4.0–10.8, P<.05). Strong and statistically significant correlations between endometrioid cancer and obesity trends were noted for Black (r=0.78, P=.01) and Hispanic (r=0.91, P<.001) women, as well as women aged 20–29 years (r=0.72, P=.03) and 30–39 years (r=0.88, P=.001). CONCLUSION: The current data demonstrate a temporal association between the increasing incidence of obesity and endometrioid endometrial cancer, and this effect disproportionately affects younger women and Black and Hispanic women.

24 August 2025 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
NMNatalie Moshayedi
Natalie Moshayedi
KCKiran Clair
Kiran Clair
AFAlex Francoeur
Alex Francoeur
Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism. Preclinical studies suggest these agents may also influence cancer progression, though further clinical research is needed. Bariatric surgery remains the most effective long-term intervention for severe obesity, offering significant metabolic and hormonal benefits. Weight loss surgery is associated with reduced cancer risk and improvements in molecular markers, though findings on specific biomarkers remain inconsistent. This narrative review explores emerging weight loss interventions, focusing on novel pharmacologic agents and bariatric surgery, and their impact on endometrial cancer risk and outcomes.

28 April 2025 in Gynecologic Oncology
Verified
Journal Article
Closed access
CJCaitlin R. Johnson
Caitlin R. Johnson
CAChinmayi Aryasomayajula
Chinmayi Aryasomayajula
AFAlex Francoeur
Alex Francoeur
CSChelsea Stewart
Chelsea Stewart
TSTiffany Y. Sia
Tiffany Y. Sia
JCJohn K. Chan
John K. Chan

31 December 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
AFAlex Francoeur
Alex Francoeur
CLCheng-I Liao
Cheng-I Liao
CJCaitlin R. Johnson
Caitlin R. Johnson
CAChris Argueta
Chris Argueta
CTChunqiao Tian
Chunqiao Tian
JCJohn K. Chan
John K. Chan